The once-weekly "jab", slow-release formulation of EXENATIDE (BYETTA), known as BYDUREON, has been approved for use in the UK. This weekly "jab" (the UK term for injection) can replace the current twice-daily injection formulation.
It'll cost £18 per week for the single "jab" (that's $27.59 with today's conversion rate) or $1435 per year.
How many of the 2.25 million UK diabetics will be using the drug? Time will tell. Keep in mind that it is estimated there are another 850,000 diabetics in the UK that are not yet diagnosed.
The final FDA decision on this drug is anticipated by late this month. Nausea is experienced by about one quarter of the patients using BYDUREON.
Read the full article here which includes a nice photo of the original source of this protein.
0 comments:
Post a Comment